A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 743-751

  Fakih, M G ^a,d   Groman, A ^b   McMahon, J ^c   Wilding, G ^b   Muindi, J R ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Colorectal; Histone deacetylase inhibitor; Phase II; Vorinostat

Indexed keywords

FLUOROURACIL; FOLINIC ACID; VORINOSTAT;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHEILITIS; COLORECTAL CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; ENTERITIS; ESOPHAGITIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFRACTORY COLORECTAL CANCER; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; HYDROXAMIC ACIDS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84859778955     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1762-1     Document Type: Article

References (45)

1. Wilson AJ et al (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281(19):13548-13558 (Pubitemid 43855268)
2. Archer SY et al (2005) The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 289(4):G696-G703 (Pubitemid 41377176)
3. Nawrocki ST et al (2007) Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 67(14):6987-6994 (Pubitemid 47105547)
4. Xu WS et al (2005) Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65(17):7832-7839
5. Place RF, Noonan EJ, Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 70(3):394-406 (Pubitemid 40905111)
6. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96(2):293-304 (Pubitemid 41437862)
7. Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36(1):110-119 (Pubitemid 36836262)
8. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13(1):1-13 (Pubitemid 34169522)
9. Liu T et al (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32(3):157-165
10. Deroanne CF et al (2002) Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427-436 (Pubitemid 34123805)
11. Conti C et al (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70(11):4470-4480
12. Owonikoko TK et al (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 126(3):743-755
13. Kirschbaum M et al (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29(9):1198-1203
14. Duvic M et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-39 (Pubitemid 46053039)
15. Traynor AM et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4(4):522-526
16. Galanis E et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12):2052-2058
17. Luu TH et al (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-7142
18. Vansteenkiste J et al (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26(5):483-488
19. Modesitt SC et al (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109(2):182-186
20. Blumenschein GR Jr et al (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-87
21. Krug LM et al (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7(4):257-261 (Pubitemid 43280028)
22. Fazzone W et al (2009) Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 125(2):463-473
23. Cheriyath V et al (2011) Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer 104(6):957-967
24. Arnold NB et al (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13(1):18-26 (Pubitemid 46121848)
25. Shi YK et al (2010) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother Pharmacol 66(6):1131-1140
26. Suzuki M et al (2009) Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64(6):1115-1122
27. Ramalingam SS et al (2010) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28(1):56-62
28. Munster PN et al (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101(7):1044-1050
29. Wilson PM et al (2010) A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 65(5):979-988
30. Fakih MG et al (2010) A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 16(14):3786-3794
31. Fakih MG et al (2009) A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15(9):3189-3195
32. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
33. Munster PN et al (2009) A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 15(22):7077-7084
34. Ramalingam SS et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13(12):3605-3610 (Pubitemid 46955122)
35. Tie J et al (2011) KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17(5):1122-1130
36. Olsen EA et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21):3109-3115 (Pubitemid 47218059)
37. Glaser KB et al (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2(2):151-163
38. Jonker DJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040-2048 (Pubitemid 350106711)
39. Rothenberg ML et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059-2069 (Pubitemid 46606353)
40. Rougier P et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138): 1407-1412 (Pubitemid 28510873)
41. Di Gennaro E et al (2009) Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 8(9):782-791
42. Kim MS et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63(21):7291-7300 (Pubitemid 37413470)
43. Novotny-Diermayr V et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9(3):642-652
44. Kelly WK et al (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9(10 Pt 1):3578-3588
45. Klampfer L et al (2007) Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: the role of signal transducers and activators of transcription 1 and p21. Cancer Res 67(18):8477-8485 (Pubitemid 47437421)